-+ 0.00%
-+ 0.00%
-+ 0.00%

Rigel Pharmaceuticals posts corporate deck highlighting VEPPANU in-license and commercial launch plan

PUBT·08/04/2026 22:33:44
Listen to the news
Rigel Pharmaceuticals posts corporate deck highlighting VEPPANU in-license and commercial launch plan
  • Rigel outlined an exclusive global license with Arvinas and Pfizer for VEPPANU (vepdegestrant) in 2L+ ER+/HER2-, ESR1-mutated metastatic breast cancer.
  • VEPPANU launch set for mid-August; positioned as the first FDA-approved oral PROTAC.
  • 2026 net product sales guidance shown at USD 260 million; portfolio sales rose 14% year over year to USD 47.4 million in Q2 2026.
  • Q2 net product sales split: TAVALISSE USD 27% higher year over year; GAVRETO USD 10.7 million; REZLIDHIA USD 8.9 million.
  • Cash balance ended 2025 at USD 155 million; strategy targets commercial expansion, pipeline advancement, financial discipline, in-licensing, M&A.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rigel Pharmaceuticals Inc. published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.